Media Coverage

KindredBio shares soar after positive mAb study results


Nov 02, 2018 - Animal Pharm
By Daniel Willis

Kindred Biosciences has seen its share price climb following positive results from a pilot study for its treatment candidate for canine atopic dermatitis.

The firm's share price rose to $14.96, up from $12.31 before the study results were revealed. Positive top-line results from the pilot effectiveness study of KindredBio's interleukin-31 (IL-31) antibody were also followed by the US Patent and Trademark Office issuing the company a patent for its IL-31 antibody.

KindredBio's stock value peaked in August this year, trading at $15.50 per share. This was the company's highest share value since August 2014. This followed the company becoming a commercial entity in July the same year, after it launched Miritaz, a transdermal ointment treatment for the management of weight loss in cats.

The company is due to release its third-quarter financial results on November 7.




Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum